Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1196333
Author(s)
Vellenga, Edo; van Putten, Wim; Ossenkoppele, Gert J; Verdonck, Leo F; Theobald, Matthias; Cornelissen, Jan J; Huijgens, Peter C; Maertens, Johan; Gratwohl, Alois; Schaafsma, Ron; Schanz, Urs; Graux, Carlos; Schouten, Harry C; Ferrant, Augustin; Bargetzi, Mario; Fey, Martin F; Löwenberg, Bob; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
Journal
Blood
Volume
118
Number
23
Pages / Article-Number
6037-42
Abstract
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy, n = 259; ASCT, n = 258), more than 90% received their assigned treatment. The 2 groups were comparable with regard to prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs 70%, P = .02) and better relapse-free survival at 5 years (38% vs 29%, P = .065, hazard ratio = 0.82; 95% confidence interval, 0.66-1.1) with nonrelapse mortality of 4% versus 1% in the chemotherapy arm (P = .02). Overall survival was similar (44% vs 41% at 5 years, P = .86) because of more opportunities for salvage with second-line chemotherapy and stem cell transplantation in patients relapsing on the chemotherapy arm. This large study shows a relapse advantage for ASCT as postremission therapy but similar survival because more relapsing patients on the chemotherapy arm were salvaged with a late transplantation for relapse. This trial is registered at www.trialregister.nl as #NTR230 and #NTR291.
